NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.
J&J said Monday it would acquire Aragon Pharmaceuticals for $650 million upfront plus up to $350 million in milestone payments, with the expectation that the deal will close in third quarter 2013.
Among the drugs under development at Aragon is ARN-509, currently in mid-stage clinical trials for castration-resistant prostate cancer. Before the deal closes, Aragon plans to transfer all of its assets other than the program to develop drugs like ARN-509 to a new spinoff company, in which J&J will not have any ownership stake. According to published reports, the new company will be called Seragon Pharmaceuticals and will be run by Aragon president and CEO Richard Heyman.
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.